AAPL307.92+13.54 (+4.60%) ▲|ABBV258.75+7.69 (+3.06%) ▲|ABT95.06+2.88 (+3.12%) ▲|ACN137.59+6.46 (+4.93%) ▲|ADBE221.29+10.31 (+4.89%) ▲|AMAT582.22-68.69 (-10.55%) ▼|AMD508.29-32.59 (-6.03%) ▼|AMGN370.97+9.64 (+2.67%) ▲|AMT167.10+1.02 (+0.61%) ▲|AMZN244.18+2.48 (+1.02%) ▲|AVGO358.48-10.86 (-2.94%) ▼|AXP349.14+2.09 (+0.60%) ▲|BA223.36+4.78 (+2.19%) ▲|BAC58.41+0.05 (+0.08%) ▲|BKNG182.11-0.53 (-0.29%) ▼|BLK990.65+10.27 (+1.05%) ▲|BMY57.13+1.32 (+2.36%) ▲|BNY145.30-0.72 (-0.49%) ▼|BRK-B505.86+6.12 (+1.22%) ▲|C138.41-1.72 (-1.23%) ▼|CAT952.74-38.67 (-3.90%) ▼|CL94.85+2.09 (+2.25%) ▲|CMCSA23.33-0.41 (-1.71%) ▼|COF203.34-1.48 (-0.72%) ▼|COP103.65+0.43 (+0.41%) ▲|COST948.52+23.85 (+2.58%) ▲|CRM165.63+2.40 (+1.47%) ▲|CSCO112.42-4.60 (-3.93%) ▼|CVS103.51-1.30 (-1.24%) ▼|CVX168.28+2.59 (+1.56%) ▲|DE616.89-10.75 (-1.71%) ▼|DHR196.52+2.80 (+1.45%) ▲|DIS98.04+2.33 (+2.43%) ▲|DUK128.25+2.48 (+1.97%) ▲|EMR137.50-2.02 (-1.45%) ▼|FDX311.28-2.61 (-0.83%) ▼|GD369.77+8.50 (+2.35%) ▲|GE374.86-0.08 (-0.02%) ▼|GEV1,096.07-38.29 (-3.38%) ▼|GILD129.82+3.85 (+3.05%) ▲|GM74.40-1.12 (-1.49%) ▼|GOOG353.34-4.55 (-1.27%) ▼|GOOGL356.52-4.70 (-1.30%) ▼|GS1,011.89-7.73 (-0.76%) ▼|HD354.31+3.47 (+0.99%) ▲|HON226.01+4.26 (+1.92%) ▲|IBM285.80-0.45 (-0.16%) ▼|INTC119.47-7.55 (-5.94%) ▼|INTU275.16+8.08 (+3.03%) ▲|ISRG421.27+18.89 (+4.69%) ▲|JNJ261.48+7.50 (+2.95%) ▲|JPM332.72-1.35 (-0.40%) ▼|KO83.07+1.78 (+2.18%) ▲|LIN545.31+11.76 (+2.20%) ▲|LLY1,207.93+16.19 (+1.36%) ▲|LMT537.11+15.29 (+2.93%) ▲|LOW224.59+2.67 (+1.20%) ▲|LRCX346.53-44.73 (-11.43%) ▼|MA536.68+14.24 (+2.73%) ▲|MCD278.21+8.78 (+3.26%) ▲|MDLZ60.43+1.08 (+1.82%) ▲|MDT82.49+3.29 (+4.15%) ▲|META584.66-28.25 (-4.61%) ▼|MMM159.84-0.13 (-0.08%) ▼|MO72.28+0.74 (+1.03%) ▲|MRK128.13+2.76 (+2.20%) ▲|MS212.02+0.16 (+0.08%) ▲|MSFT390.75+6.47 (+1.68%) ▲|MU962.11-70.17 (-6.80%) ▼|NEE87.29+0.92 (+1.06%) ▲|NFLX78.19+4.00 (+5.39%) ▲|NKE43.95+0.89 (+2.07%) ▲|NOW106.02+0.22 (+0.21%) ▲|NVDA193.10-4.48 (-2.27%) ▼|ORCL139.27-3.23 (-2.27%) ▼|PEP143.74+2.58 (+1.83%) ▲|PFE24.28+0.40 (+1.65%) ▲|PG151.04+3.61 (+2.45%) ▲|PLTR131.35+5.62 (+4.47%) ▲|PM180.47+2.78 (+1.56%) ▲|QCOM173.30-8.62 (-4.74%) ▼|RTX196.72+4.94 (+2.58%) ▲|SBUX104.01+0.62 (+0.60%) ▲|SCHW96.54+0.76 (+0.79%) ▲|SO97.26+2.14 (+2.25%) ▲|SPG224.69+1.69 (+0.76%) ▲|T20.12-0.37 (-1.78%) ▼|TMO520.06+6.73 (+1.31%) ▲|TMUS174.81+1.75 (+1.01%) ▲|TSLA392.09-33.22 (-7.81%) ▼|TXN289.85-8.57 (-2.87%) ▼|UBER73.36+0.70 (+0.96%) ▲|UNH422.34-4.20 (-0.98%) ▼|UNP280.32+2.59 (+0.93%) ▲|UPS109.48-0.07 (-0.06%) ▼|USB61.30-0.66 (-1.07%) ▼|V359.66+8.58 (+2.44%) ▲|VZ41.48-0.52 (-1.23%) ▼|WFC85.18-0.76 (-0.88%) ▼|WMT111.84+3.02 (+2.77%) ▲|XOM136.93+0.65 (+0.48%) ▲|AAPL307.92+13.54 (+4.60%) ▲|ABBV258.75+7.69 (+3.06%) ▲|ABT95.06+2.88 (+3.12%) ▲|ACN137.59+6.46 (+4.93%) ▲|ADBE221.29+10.31 (+4.89%) ▲|AMAT582.22-68.69 (-10.55%) ▼|AMD508.29-32.59 (-6.03%) ▼|AMGN370.97+9.64 (+2.67%) ▲|AMT167.10+1.02 (+0.61%) ▲|AMZN244.18+2.48 (+1.02%) ▲|AVGO358.48-10.86 (-2.94%) ▼|AXP349.14+2.09 (+0.60%) ▲|BA223.36+4.78 (+2.19%) ▲|BAC58.41+0.05 (+0.08%) ▲|BKNG182.11-0.53 (-0.29%) ▼|BLK990.65+10.27 (+1.05%) ▲|BMY57.13+1.32 (+2.36%) ▲|BNY145.30-0.72 (-0.49%) ▼|BRK-B505.86+6.12 (+1.22%) ▲|C138.41-1.72 (-1.23%) ▼|CAT952.74-38.67 (-3.90%) ▼|CL94.85+2.09 (+2.25%) ▲|CMCSA23.33-0.41 (-1.71%) ▼|COF203.34-1.48 (-0.72%) ▼|COP103.65+0.43 (+0.41%) ▲|COST948.52+23.85 (+2.58%) ▲|CRM165.63+2.40 (+1.47%) ▲|CSCO112.42-4.60 (-3.93%) ▼|CVS103.51-1.30 (-1.24%) ▼|CVX168.28+2.59 (+1.56%) ▲|DE616.89-10.75 (-1.71%) ▼|DHR196.52+2.80 (+1.45%) ▲|DIS98.04+2.33 (+2.43%) ▲|DUK128.25+2.48 (+1.97%) ▲|EMR137.50-2.02 (-1.45%) ▼|FDX311.28-2.61 (-0.83%) ▼|GD369.77+8.50 (+2.35%) ▲|GE374.86-0.08 (-0.02%) ▼|GEV1,096.07-38.29 (-3.38%) ▼|GILD129.82+3.85 (+3.05%) ▲|GM74.40-1.12 (-1.49%) ▼|GOOG353.34-4.55 (-1.27%) ▼|GOOGL356.52-4.70 (-1.30%) ▼|GS1,011.89-7.73 (-0.76%) ▼|HD354.31+3.47 (+0.99%) ▲|HON226.01+4.26 (+1.92%) ▲|IBM285.80-0.45 (-0.16%) ▼|INTC119.47-7.55 (-5.94%) ▼|INTU275.16+8.08 (+3.03%) ▲|ISRG421.27+18.89 (+4.69%) ▲|JNJ261.48+7.50 (+2.95%) ▲|JPM332.72-1.35 (-0.40%) ▼|KO83.07+1.78 (+2.18%) ▲|LIN545.31+11.76 (+2.20%) ▲|LLY1,207.93+16.19 (+1.36%) ▲|LMT537.11+15.29 (+2.93%) ▲|LOW224.59+2.67 (+1.20%) ▲|LRCX346.53-44.73 (-11.43%) ▼|MA536.68+14.24 (+2.73%) ▲|MCD278.21+8.78 (+3.26%) ▲|MDLZ60.43+1.08 (+1.82%) ▲|MDT82.49+3.29 (+4.15%) ▲|META584.66-28.25 (-4.61%) ▼|MMM159.84-0.13 (-0.08%) ▼|MO72.28+0.74 (+1.03%) ▲|MRK128.13+2.76 (+2.20%) ▲|MS212.02+0.16 (+0.08%) ▲|MSFT390.75+6.47 (+1.68%) ▲|MU962.11-70.17 (-6.80%) ▼|NEE87.29+0.92 (+1.06%) ▲|NFLX78.19+4.00 (+5.39%) ▲|NKE43.95+0.89 (+2.07%) ▲|NOW106.02+0.22 (+0.21%) ▲|NVDA193.10-4.48 (-2.27%) ▼|ORCL139.27-3.23 (-2.27%) ▼|PEP143.74+2.58 (+1.83%) ▲|PFE24.28+0.40 (+1.65%) ▲|PG151.04+3.61 (+2.45%) ▲|PLTR131.35+5.62 (+4.47%) ▲|PM180.47+2.78 (+1.56%) ▲|QCOM173.30-8.62 (-4.74%) ▼|RTX196.72+4.94 (+2.58%) ▲|SBUX104.01+0.62 (+0.60%) ▲|SCHW96.54+0.76 (+0.79%) ▲|SO97.26+2.14 (+2.25%) ▲|SPG224.69+1.69 (+0.76%) ▲|T20.12-0.37 (-1.78%) ▼|TMO520.06+6.73 (+1.31%) ▲|TMUS174.81+1.75 (+1.01%) ▲|TSLA392.09-33.22 (-7.81%) ▼|TXN289.85-8.57 (-2.87%) ▼|UBER73.36+0.70 (+0.96%) ▲|UNH422.34-4.20 (-0.98%) ▼|UNP280.32+2.59 (+0.93%) ▲|UPS109.48-0.07 (-0.06%) ▼|USB61.30-0.66 (-1.07%) ▼|V359.66+8.58 (+2.44%) ▲|VZ41.48-0.52 (-1.23%) ▼|WFC85.18-0.76 (-0.88%) ▼|WMT111.84+3.02 (+2.77%) ▲|XOM136.93+0.65 (+0.48%) ▲|
37.8 C
New York
Thursday, July 2, 2026

Tag: research

Viridian Metals Outlines Basin-Scale Copper Targets and Structural Controls at Sedna and Results of AGSM

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, July 31, 2025 /CNW/ - Viridian Metals Inc....

Lightspeed Announces First Quarter 2026 Financial Results

Total revenue in the quarter of $304.9 million grew 15% year-over-year and exceeded outlook Gross margin improved to 42%, with gross profit increasing 19% year-over-year exceeding...

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.

PL BioScience Announces Major Site Expansion

AACHEN, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a significant expansion of company headquarters and future manufacturing capabilities to meet the rapidly growing global demand for safe, animal-free cell culture supplements.

Consolidated unaudited interim report for the II quarter and first 6 months of 2025

A webinar on the presentation of the results (in Estonian only) will take place on 31 July at 13:00 (EEST), more information.

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range


Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration

VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.

Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone

SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...

Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone

SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

FMC Corporation Reports Second Quarter Results at High End of Guidance Range

Maintains full year adjusted EBITDA and adjusted EPS guidance; announces sale of India commercial business Second Quarter 2025 Highlights Revenue of $1.05 billion, up 1...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch